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China Needs Evidence-Based Medicine (EBM)
China is the biggest country in the world that has 1.3
billion population. The health of the population has
been one of the issues most relevant to sustainable
development of the economy and society. However,
limited availability of health services is unable to meet
the enormous health needs. The estimated annual inci-
dence of cancers 1.3%, cardiovascular diseases 50%,
infection diseases 2.7% in 2003, whereas only 1.50
clinicians, 1.03 nurses and 2.40 ward beds per thou-
sand are available to provide services in 2004 [1]. With
the rapid shift of infectious diseases to chronic diseases
in the Chinese population, the health spending is
increased dramatically. The national health expendi-
ture in 2003 has been tripled to 658.41 billion Ren-
minbi (RMB) compared to that in 1995 [1], whereas
an increase of national health budget from 38.734
billion in 1995 to 111.694 billion in 2003 [2] cannot
cope with the steep climbing of health expenditure. It
is a big challenge to utilize the limited health-care
capacity to keep all the population healthy.
On the other hand, the health resource use is highly
imbalanced across China. In the economically devel-
oped regions, the health-care services are improperly
and excessively utilized, whereas health professionals
and technologies are less available in regions with less
developed economy. This situation has been further
complicated by the low efﬁciency of utilizations of
health services, on which a large number of avoidable
adverse events of medications occur each year to cause
additional health resource use.
Since early 1990s, these problems have been
increasingly evident in China. Although the central
and local government paid great efforts to address
these problems, the health-care system is yet to be
improved. The World Health Organization (WHO)
Report [2] ranked China 144th place out of 191
member countries for the overall health services. Both
policymakers and clinicians feel the strong need to
make policy and clinical decisions based on solid
evidence. Coincidently occurred in the world was
the burgeoning of the international organization in
1993—the Cochrane Collaboration—which aims to
produce, maintain, and disseminate the best evidence
to improve the effects of health care, and a new ﬁeld in
clinical medicine in 1992—EBM—that focuses on
improving the health-care pattern. These historical
events have become the incentives that promoted the
introduction and development of EBM in China.
Development of Research and Practice
Platforms in China
In November 1997, the Chinese Evidence-Based Medi-
cine Center (CEBMC) was approved to be established
at West China University of Medical Sciences. In 1999,
the Chinese Cochrane Center, which is also based at
West China University of Medical Sciences, was suc-
cessfully registered with the Cochrane Collaboration.
In 2002, the Chinese Cochrane Center developed its
Hong Kong branch at the Chinese University of Hong
Kong.
The value and potential of EBM in medical educa-
tion were recognized by the Chinese Ministry of Edu-
cation. In 2002, the Virtual Research Center of EBM
(Ministry of Education) was approved. The following
year, the discipline of EBM was approved by the Min-
istry of Education to train the ﬁrst group of postgradu-
ates for the future researchers and policymakers.
EBM in the Policymaking Process:
The Government Efforts
Development of EBM and Use of Evidence in the
Ministry of Health
The birth and development of Chinese EBM is attrib-
utable to the Chinese Ministry of Health. On the
contrary, the development of EBM also beneﬁts the
Ministry for the development of varieties of policies.
The Chinese Ministry of Health is the major regulation
body of the medical policy in China. To improve the
efﬁciency of decision-making, the Health Technology
Admission Ofﬁce was established, which applied the
best available evidence in major policymaking. Since
the establishment of the Ofﬁce, varieties of health tech-
nology programs were assessed, including aided repro-
ductive technology, legislation of brain death, medical
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risk management, development specialist training
systems, and development of evidence-based clinical
practice guidelines.
National Science Foundation of China
The value of EBM for policymaking was ﬁrst recog-
nized by the National Science Foundation of China in
1996. Early in the new millennium, the foundation
reported to the State Council that EBM was one of the
few science subjects in China that could be in line with
the research cutting edge in the world. In 2005, the
foundation established the ﬁrst fund for EBM.
Application of Evidence in Reproductive
Health Policymaking
At the request of the WHO, China started the program
of evidence-based evaluation of reproductive technolo-
gies in 2001. In 2003, the WHO took efforts to evalu-
ate these technologies for inclusion of WHO Model
List of Essential Medicines. Two years after the WHO
initiative, China attempted to develop a system to
monitor, assess, and manage the risk of the contracep-
tion devices. The evidence prepared will be used for the
system, and the concept of EBM will also be incorpo-
rated into the decision process that monitors and
selects the devices efﬁciently.
EBM for Medicines Evaluation in the State Food and
Drug Administration
At the request of WHO, China started its program on
evidence-based evaluation and selection of essential
medicines 2001. In 2002, a program on evidence-
based evaluation of three categories of pharmaceuti-
cals and traditional Chinese medicines (TCM) for
inclusion to the National Essential Medicines List was
commissioned. The methods of health technology
assessment were used by identifying clinical and eco-
nomic evidence of these medicines, and critically
appraising their validity and generalizability in the
context of the Chinese setting. In 2004, an updated
selection of essential medicines was developed, in
which the prioritized medicines were assessed system-
atically by identifying and critically appraising the evi-
dence. This was a signiﬁcant milestone of EBM in
terms of its use in the evidence-based policymaking.
In 2005, methods for pharmacoeconomic analysis
of essential medicines in the Chinese setting were
developed. In 2006, the draft of the guide of pharma-
coeconomic analysis has been circulated and received
praise for the initiative.
Bureau of TCM
From 2000, the topic of EBM has been the key method
to promote the internalization and standardization of
TCM and has been incorporated into the main grant
application for TCM research.
Ministry of Education
The EBM has been highly emphasized in the medical
education. In 2003, the ﬁrst text book of EBM for the
undergraduate medical students was published. With
the further development and dissemination in the
Chinese universities, an edition of the national text-
book of EBM for medical undergraduate students was
proposed in 2006. In the same year, the 4th Asian-
Paciﬁc Conference on EBM was held with the joint
efforts of the Ministry of Health and Ministry of
Education.
Military Department of Health
The Military Department of Health started its EBM
practice in 2002. In 2003, the severe acute respiratory
syndrome broke out, of which China was the most
attacked country. In the following year, the experiences
of managing the emergent disease were proposed to
summarize. The methods of EBM were used in the
evidence preparation and policymaking processes. In
2006, the 11th National Five-Year Development
program was initiated. A proposal of developing a
system of evidence-based rational use of medicines was
made and successfully approved.
EBM Practice and Exploration:
Nongovernmental Organizations
Chinese Cochrane Center, CEBMC, and Ministry of
Education Virtual Research Center of EBM
Since 1998, the Chinese Cochrane Center and CEBMC
opened courses on EBM for 3000 undergraduates,
2500 graduates, and 217 residents. More than 200
lectures and workshops involving 40,000 participants
have taken place since 1998. The Ministry of Educa-
tion EBM Training Programme that started in 2004
appointed the centers to train university teachers who
teach EBM and a total of 265 lecturers have been
trained through the course.
Educational efforts include the development of
Chinese Clinical Trial Database that hand searched
109 Chinese journals and identiﬁed more than 10,000
trials, of which 1500–2000 trials were submitted to the
Cochrane CENTRAL register per year. The production
of Cochrane systematic reviews has rapidly increased.
By the end of 2005, 108 titles, 75 protocols and 28
reviews were produced from the Chinese reviewers.
The rate of increase of contributors and authors in
China is more than 10 times of the Cochrane Collabo-
ration. China has been in the list of the 10 countries
with the most contributors to the work of the
Cochrane Review Groups since 2004, and the only
country in this short list categorized as low or middle
income by The World Bank.
Chinese Medical Doctor Association (CMDA). The
CMDA was established in 2001. Just upon its estab-
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lishment, the EBM was highlighted. In 2004, the EBM
subcommittee was established under the CMDA.
Chinese Medical Association. Since 2002, the Chinese
Medical Association recognized the value of EBM.
EBM in universities. Many other Chinese universities
have developed their university-based center for EBM,
including Beijng University, Fudan University, Lan
Zhou University, Guang Xi University of Medical Sci-
ences, and Zhe Jiang University. Several universities
have developed courses for EBM postgraduate and
undergraduate courses.
Conclusions
The birth and development of EBM in China was a
result of practical needs, governmental support, and
international efforts. The further development of EBM
will be full of challenge and opportunity. But we are
conﬁdent to promote further the development in
China. The EBM in China is part of the world efforts,
and the world involvement in EBM cannot be without
the Chinese role.
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Introduction
From the year 2000, the national drug expenditure has
seen an increase from RM346 million ($91 million) to
RM915 million ($241 million) in 2005. From the year
2004 to 2005, an increase of 13.3% was recorded [1].
Factors that may contribute to this increase include
increase in drug prices, a growing and aging popula-
tion, higher expectation of the public regarding equal-
ity in assessing therapy, long-term drug treatment and
polypharmacy, improvements in diagnosis and treat-
ment of diseases, and technological advancement that
produces newer expensive drugs [2,3].
Drug Registration and Regulation in Malaysia
A statutory body known as the Drug Control Author-
ity (DCA) is responsible to ensure that medicines mar-
keted in Malaysia are safe, efﬁcacious, and of quality.
This is done through a systematic registration, licens-
ing, and surveillance scheme which is part of a man-
datory product registration process. The National
Pharmaceutical Control Bureau is an organization
under the Pharmacy Division. It is responsible for the
Quality Assurance program and performs the opera-
tional function of the DCA. This include activities such
as product evaluation, product assessment (laboratory
testing), Good Manufacturing Practice inspections,
processing of product certiﬁcate and licences, postmar-
keting surveillance, and monitoring of Adverse Drug
Reaction.
Malaysian Ministry of Health (MOH)
Drug Formulary
InMalaysia, drugs that aremade available for use in the
public health-care system are controlled through the
MOH Drug Formulary. The MOH Drug List was ﬁrst
introduced in 1983 and contains a list of drugs that have
been approved for use in the MOH hospitals and
institutions. The use of nonformulary drugs requires
prior authorization and approval by the Director-
General of Health. The use of this formulary does not
include the private hospitals and teaching hospitals. By
the end of 2005, there were 1322 preparations listed in
the formulary. Drugs in the formulary are classiﬁed
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